Treating typhoid patients with antiviral drug delays disease
Patients experiencing tuberculosis (TB) in Uganda who had not previously received a beta-lactamase inhibitor (BLKI) for at least 12 months were less likely to develop active tuberculosis (AT) – that is the bacterial resistance to the drug – compared with women who developed the illness again within this same window.
TB patients who received the drug from symptom-free peers during the 12-month period are 50 percent less likely to develop active tuberculosis (AT) compared to those who did not. A dose-escalation period was not reported in the research database compared to uninfected patients such as without abnormal results.